Professor Mark Hatherill

Director, South African Tuberculosis Vaccine Initiative (SATVI) University of Cape Town

Professor Mark Hatherill is Director and leader of the clinical research team of the South African Tuberculosis Vaccine Initiative (SATVI), a University of Cape Town research group focused on understanding risk for and protection against TB, to develop better vaccines and preventive therapies to impact the global epidemic.

A University of Cape Town medical graduate, he trained as a pediatrician and critical care sub-specialist. Since 2005, SATVI has conducted 28 clinical trials of 9 novel TB vaccine candidates involving almost 6,000 participants, in addition to large epidemiological and immunological cohort studies. Prof Hatherill played a lead role in efficacy trials that tested the candidate vaccine MVA85A for prevention of TB disease in infants; BCG revaccination for prevention of M. tuberculosis infection in adolescents; and the candidate vaccine M72/ASO1E for prevention of TB disease in adults. He is Co-PI of the Regional Prospective Observational Research in Tuberculosis (RePORT) South Africa consortium. His current work focuses on the design and implementation of clinical trials of novel TB vaccines and biomarker-targeted TB prevention.